Maya Martinez-Davis
Corporate Officer/Principal bij GSK PLC
Profiel
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Actieve functies van Maya Martinez-Davis
Bedrijven | Functie | Begin |
---|---|---|
GSK PLC | Corporate Officer/Principal | 01-01-2020 |
Eerdere bekende functies van Maya Martinez-Davis
Bedrijven | Functie | Einde |
---|---|---|
MIRATI THERAPEUTICS | Director/Board Member | 23-01-2024 |
MERCK KGAA | Corporate Officer/Principal | 01-08-2019 |
Opleiding van Maya Martinez-Davis
St. Louis University | Undergraduate Degree |
Instituto de Empresa SL | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MERCK KGAA | Health Technology |
GSK PLC | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |